Use Of A Dpp-4 Inhibitor In Podocytes Related Disorders And/or Nephrotic Syndrome

Abstract

The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.


Claims
Owners (US)

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Feb 5, 2019
  • Application: Nov 17, 2016
    US US 201615354053 A
  • Priority: Nov 17, 2016
    US US 201615354053 A
  • Priority: Oct 30, 2015
    US US 201514928048 A
  • Priority: May 13, 2013
    US US 201313892529 A
  • Priority: Oct 29, 2012
    EP EP 12190447 A
  • Priority: Sep 28, 2012
    EP EP 12006812 A
  • Priority: Jun 5, 2012
    EP EP 12170888 A
  • Priority: May 14, 2012
    EP EP 12167953 A

Download Citation


Sign in to the Lens

Feedback